Vir Biotechnology, Inc. and GlaxoSmithKline plc today announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild ... Jan 12
Merck announced the U.S. FDA accepted for priority review a Biologics License Application for V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, for ... Jan 12
-Advertisements-